+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antisense and RNAi Therapeutics Market

  • PDF Icon

    Report

  • 200 Pages
  • March 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5947425
The global antisense and RNAi therapeutics market size was estimated to be USD 5.24 billion in 2023 and is estimated to reach USD 34.70 billion by 2034 with a CAGR of 18.75% during the forecast period 2024-2034. The market will grow as a result of developing trends in molecular biology and genomics, growing emphasis on personalized medicine, rising prevalence of genetic and chronic diseases, and partnerships and collaborations.

Targeted therapies are in high demand due to the increasing prevalence of genetic abnormalities, cancer, and chronic diseases. Treatment for particular genetic defects can be personalized with antisense and RNA interference therapies. The ability to customize antisense and RNAi medicines for each patient could result in more focused and efficient medical interventions. For instance, Regulus Therapeutics and Pfizer announced in January 2024 that they will be working together to develop and market RG6042, an experimental microRNA inhibitor intended to treat idiopathic pulmonary fibrosis (IPF).

By technology, the antisense RNA segment accounted for the highest revenue-grossing segment in the global antisense and RNAi therapeutics market in 2023 owing to the increased recognition of its precision in targeting specific genes, advancements in delivery technologies, and successful outcomes in clinical trials across various therapeutic applications. For instance, Biogen and Alnylam partnered in February 2024 to develop and market ALN-HTT02, an experimental RNA interference treatment for Huntington's disease. Additionally, the RNA interference segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding scope of therapeutic applications, continuous technological advancements, and a robust pipeline of RNAi-based drug candidates demonstrating promising results in preclinical and clinical studies.

By application, the neurodegenerative disorders segment accounted for the highest revenue-grossing segment in the global antisense and RNAi therapeutics market in 2023 owing to the increasing prevalence of conditions like Alzheimer's and Parkinson's, coupled with a growing understanding of the genetic factors contributing to these disorders and the successful development of targeted RNA-based therapies. For instance, in September 2023, Moderna received approval from Health Canada to use mRNA-1273.214 (Spikevax Bivalent Original/Omicron), a COVID-19 booster vaccine. Additionally, the genetic disorders segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding genetic disease landscape, advancements in precision medicine, and the development of novel antisense and RNAi therapeutics targeting specific genetic mutations associated with rare and common genetic disorders.

By route of administration, the intrathecal injections segment accounted for the highest revenue-grossing segment in the global antisense and RNAi therapeutics market in 2023 owing to its targeted delivery to the central nervous system, which is crucial for treating neurodegenerative disorders, and advancements in drug delivery technologies enhancing the efficacy of therapeutics administered via this route. For instance, in February 2024, Biogen and Roche Holding AG partnered to develop and market ALN-HTT02, an experimental RNA interference treatment for Huntington's disease. Additionally, the subcutaneous injection segment is predicted to grow at the fastest CAGR during the forecast period owing to its convenience, patient-friendly administration, and advancements in formulation technologies, making it an attractive and accessible option for the delivery of antisense and RNAi therapeutics.

By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global antisense and RNAi therapeutics market in 2023 owing to the increasing adoption of these therapies in mainstream medical practices, growing patient access, and the establishment of specialized treatment centers focusing on the administration and management of antisense and RNAi therapeutics. For instance, Ionis Pharmaceuticals reported encouraging outcomes from a Phase 2 clinical trial of IONIS-HTT001 for Huntington's disease in February 2024. Additionally, the research institutions segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased collaboration between academia and industry, rising academic interest in antisense and RNAi technologies, and the pivotal role research institutions play in advancing the understanding and development of innovative therapeutic applications.

North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established pharmaceutical industry, robust research infrastructure, and favorable regulatory environment to support the expansion Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding healthcare infrastructure, rising awareness of genetic disorders, increasing investment in research and development, and a growing emphasis on precision medicine and personalized therapies in the region. For instance, Sarepta Therapeutics and Roche announced a partnership in January 2024 to develop and market SRP-9001, an experimental gene therapy for Duchenne muscular dystrophy.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

  • Base Year: 2023
  • Forecast Period: 2024-2034

Study Coverage

  • Market Forecast by Technology, Application, Route of Administration, and End-User
  • Market Forecast for 5 Regions and 17+ Countries
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
  • Exhaustive Company Profiles of the Top 10+ Major Market Players
  • 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Antisense and RNAi Therapeutics Market Report 2023 - 2034

Antisense and RNAi Therapeutics Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)

  • RNA Interference
  • Antisense RNA

Antisense and RNAi Therapeutics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)

  • Genetic Disease
  • Cancer
  • Infectious Disease
  • Neurodegenerative Disorders
  • Cardiometabolic & Renal Disorders
  • Ocular Disorders
  • Respiratory Disorders
  • Skin Disorders

Antisense and RNAi Therapeutics Market Analysis & Forecast by Route of Application 2023 - 2034 (Revenue USD Bn)

  • Intravenous Injections
  • Intrathecal Injections
  • Subcutaneous Injections
  • Others

Antisense and RNAi Therapeutics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

  • Hospitals and Clinics
  • Research Institutions

Antisense and RNAi Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Antisense and RNAi Therapeutics Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Antisense and RNAi Therapeutics Market: Technology Estimates & Trend Analysis
7.1. Technology Segment Opportunity Analysis
7.2. RNA Interference
7.2.1. RNA Interference Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Antisense RNA
7.3.1. Antisense RNA Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. Antisense and RNAi Therapeutics Market: Application Estimates & Trend Analysis
8.1. Application Segment Opportunity Analysis
8.2. Genetic Disease
8.2.1. Genetic Disease Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Cancer
8.3.1. Cancer Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.4. Infectious Disease
8.4.1. Infectious Disease Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.5. Neurodegenerative Disorders
8.5.1. Neurodegenerative Disorders Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.6. Cardiometabolic & Renal Disorders
8.6.1. Cardiometabolic & Renal Disorders Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.7. Ocular Disorders
8.7.1. Ocular Disorders Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.8. Respiratory Disorders
8.8.1. Respiratory Disorders Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.9. Skin Disorders
8.9.1. Skin Disorders Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Antisense and RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis
9.1. Route of Administration Segment Opportunity Analysis
9.2. Intravenous Injections
9.2.1. Intravenous Injections Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.3. Intrathecal Injections
9.3.1. Intrathecal Injections Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.4. Subcutaneous Injections
9.4.1. Subcutaneous Injections Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.5. Others
9.5.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10. Antisense and RNAi Therapeutics Market: End-user Estimates & Trend Analysis
10.1. End-user Segment Opportunity Analysis
10.2. Hospitals and Clinics
10.2.1. Hospitals and Clinics Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.3. Research Institutions
10.3.1. Research Institutions Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
11. Regional Market Analysis
11.1. Regional Market Opportunity Analysis
12. North America Antisense and RNAi Therapeutics Market
12.1. North America Antisense and RNAi Therapeutics Market
12.1.1. North America Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. North America Antisense and RNAi Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. North America Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
12.1.4. North America Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
12.1.5. North America Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.1.6. North America Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
12.2. U.S. Global Antisense and RNAi Therapeutics Market
12.2.1. U.S. Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. U.S. Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
12.2.3. U.S. Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
12.2.4. U.S. Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.2.5. U.S. Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
12.3. Canada Global Antisense and RNAi Therapeutics Market
12.3.1. Canada Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. Canada Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
12.3.3. Canada Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
12.3.4. Canada Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.3.5. Canada Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13. Europe Antisense and RNAi Therapeutics Market
13.1. Europe Antisense and RNAi Therapeutics Market
13.1.1. Europe Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.1.4. Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.1.5. Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.1.6. Europe Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.2. Germany Global Antisense and RNAi Therapeutics Market
13.2.1. Germany Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Germany Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.2.3. Germany Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.2.4. Germany Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.2.5. Germany Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.3. UK Global Antisense and RNAi Therapeutics Market
13.3.1. UK Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. UK Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.3.3. UK Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.3.4. UK Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.3.5. UK Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.4. France Global Antisense and RNAi Therapeutics Market
13.4.1. France Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. France Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.4.3. France Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.4.4. France Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.4.5. France Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.5. Spain Global Antisense and RNAi Therapeutics Market
13.5.1. Spain Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. Spain Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.5.3. Spain Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.5.4. Spain Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.5.5. Spain Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.6. Italy Global Antisense and RNAi Therapeutics Market
13.6.1. Italy Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.6.2. Italy Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.6.3. Italy Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.6.4. Italy Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.6.5. Italy Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
13.7. Rest of Europe Antisense and RNAi Therapeutics Market
13.7.1. Rest of Europe Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.7.2. Rest of Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
13.7.3. Rest of Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
13.7.4. Rest of Europe Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.7.5. Rest of Europe Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14. Asia Pacific Antisense and RNAi Therapeutics Market
14.1. Asia Pacific Antisense and RNAi Therapeutics Market
14.1.1. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.1.4. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.1.5. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.1.6. Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.2. Japan Global Antisense and RNAi Therapeutics Market
14.2.1. Japan Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. Japan Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.2.3. Japan Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.2.4. Japan Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.2.5. Japan Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.3. China Global Antisense and RNAi Therapeutics Market
14.3.1. China Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. China Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.3.3. China Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.3.4. China Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.3.5. China Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.4. India Global Antisense and RNAi Therapeutics Market
14.4.1. India Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. India Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.4.3. India Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.4.4. India Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.4.5. India Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.5. South Korea Global Antisense and RNAi Therapeutics Market
14.5.1. South Korea Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.5.2. South Korea Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.5.3. South Korea Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.5.4. South Korea Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.5.5. South Korea Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.6. Australia Global Antisense and RNAi Therapeutics Market
14.6.1. Australia Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.6.2. Australia Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.6.3. Australia Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.6.4. Australia Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.6.5. Australia Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
14.7. Rest of Asia Pacific Antisense and RNAi Therapeutics Market
14.7.1. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.7.2. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
14.7.3. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
14.7.4. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.7.5. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
15. Latin America Antisense and RNAi Therapeutics Market
15.1. Latin America Antisense and RNAi Therapeutics Market
15.1.1. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.1.2. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
15.1.3. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
15.1.4. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
15.1.5. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.1.6. Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
15.2. Brazil Global Antisense and RNAi Therapeutics Market
15.2.1. Brazil Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.2.2. Brazil Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
15.2.3. Brazil Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
15.2.4. Brazil Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.2.5. Brazil Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
15.3. Mexico Global Antisense and RNAi Therapeutics Market
15.3.1. Mexico Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.3.2. Mexico Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
15.3.3. Mexico Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
15.3.4. Mexico Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.3.5. Mexico Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
15.4. Argentina Global Antisense and RNAi Therapeutics Market
15.4.1. Argentina Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.4.2. Argentina Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
15.4.3. Argentina Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
15.4.4. Argentina Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.4.5. Argentina Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
15.5. Rest of Latin America Antisense and RNAi Therapeutics Market
15.5.1. Rest of Latin America Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.5.2. Rest of Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
15.5.3. Rest of Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
15.5.4. Rest of Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.5.5. Rest of Latin America Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
16. MEA Antisense and RNAi Therapeutics Market
16.1. MEA Antisense and RNAi Therapeutics Market
16.1.1. MEA Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.1.2. MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
16.1.3. MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
16.1.4. MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
16.1.5. MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.1.6. MEA Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
16.2. GCC Global Antisense and RNAi Therapeutics Market
16.2.1. GCC Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.2.2. GCC Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
16.2.3. GCC Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
16.2.4. GCC Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.2.5. GCC Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
16.3. South Africa Global Antisense and RNAi Therapeutics Market
16.3.1. South Africa Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.3.2. South Africa Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
16.3.3. South Africa Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
16.3.4. South Africa Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.3.5. South Africa Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
16.4. Rest of MEA Antisense and RNAi Therapeutics Market
16.4.1. Rest of MEA Antisense and RNAi Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.4.2. Rest of MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Technology, 2023-2034 (Revenue USD Bn)
16.4.3. Rest of MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Application, 2023-2034 (Revenue USD Bn)
16.4.4. Rest of MEA Antisense and RNAi Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.4.5. Rest of MEA Antisense and RNAi Therapeutics Market Size and Forecast, By End-user, 2023-2034 (Revenue USD Bn)
17. Competitor Analysis
17.1. Company Market Share Analysis, 2023
17.2. Major Recent Developments
18. Company Profiles
18.1. Alnylam Pharmaceuticals, Inc.
18.2. Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
18.3. Sarepta Therapeutics, Inc.
18.4. Novartis AG
18.5. Silence Therapeutics
18.6. Moderna, Inc.
18.7. Biogen Inc.
18.8. Arrowhead Pharmaceuticals, Inc.
18.9. Regulus Therapeutics Inc.
18.10. Dicerna Pharmaceuticals, Inc.
18.11. Sirnaomics, Inc.
18.12. Roche Holding AG
18.13. Pfizer Inc.
18.14. Johnson & Johnson
19. Conclusion20. Recommendations

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Ionis Pharmaceuticals (Akcea Therapeutics Inc.)
  • Sarepta Therapeutics Inc.
  • Novartis AG
  • Silence Therapeutics
  • Arbutus Biopharma
  • Moderna Inc.
  • Biogen Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Regulus Therapeutics Inc.
  • Dicerna Pharmaceuticals Inc.
  • Sirnaomics Inc.
  • Roche Holding AG
  • Pfizer Inc.
  • Johnson & Johnson

Table Information